Gleitz Lab

Department of Developmental Biology

Erasmus MC, Rotterdam

Research

Our research on myeloproliferative neoplasms (MPN) is guided by the overarching question of how mutations acquired in bone marrow stem cells interact with their surrounding niche, lead to a remodeling of the bone marrow microenvironment and ultimately lead to the inability to produce blood.

We use a combination of murine models, patient samples, single-cell sequencing, and methylation technology to understand the cellular and molecular ‘cues’ that are triggered by mutations in stem cells and how their interaction with other surrounding cells is affected, leading to the replacement of normal blood-forming cells by fibrotic tissue.

Moreover, we seek to clarify the downstream effects of chronic inflammation and myeloproliferation on the cellular crosstalk with other organs, such as the brain/central nervous system. The ultimate goal is to be able to identify new therapeutic targets to treat and improve the prognosis of myeloproliferative neoplasm (MPN) patients.

Publications

2024

Fuchs SNR, Stalmann USA, Snoeren IAM, Bindels E,... Gleitz HFE*, Schneider RK*. Collaborative effect of Csnk1a1 haploinsufficiency and mutant p53 in Myc induction can promote leukemic transformation. Blood Adv. 2024.

Pritchard JE, Pearce JE, Snoeren IAM,... Gleitz HFE, Kramann R, Schneider RK. Non-canonical Hedgehog signaling mediates profibrotic hematopoiesis-stroma crosstalk in myeloproliferative neoplasms. Cell Rep. 2024.

2023

Ellison S, Liao A, Gleitz HFE, Parker H, Booth L, Robinson J, Wood S, Taylor J, Holley R, Bigger BW. Sustained long-term disease correction in a murine model of MPSII following stem cell gene therapy. Mol Ther Methods Clin Dev. 2023

Wood SR, Chaudrhy A, Ellison S, Searle R, Burgod C, Tehseen G, Forte G, O'Leary C, Gleitz H, Liao A, Cook J, Holley R, Bigger BW. Fusion of Rabies Virus Glycoprotein or gh625 to Iduronate-2-Sulfatase for the Treatment of Mucopolysaccharidosis Type II. Hum Gene Ther. 2023

Mascarenhas J, Gleitz HFE, Chifotides HT, Harrison CN, Verstovsek S, Vannucchi AM, Rampal RK, Kiladjian JJ, Vainchenker W, Hoffman R, Schneider RK, List AF. Biological drivers of clinical phenotype in myelofibrosis. Leukemia. 2023

Gleitz HFE, Schneider RK. "ASXL1"-erating inflammation and bone marrow fibrosis in myeloproliferative neoplasms. Haematologica. 2023

2022

Stalmann USA, Ticconi F, Snoeren IAM, Li R, Gleitz H,... and Schneider RK. Genetic barcoding systematically comparing genes in del(5q) MDS reveals a central role for CSNK1A1 in clonal expansion. Blood Adv. 2022

2021

Gleitz HFE, Benabid A, Schneider RK. Still a burning question: the interplay between inflammation and fibrosis in myeloproliferative neoplasms. Curr Opin Hematol. 2021

Gleitz HFE, Snoeren IAM, Fuchs SNR, Leimkühler NB, Schneider RK. Isolation of human bone marrow stromal cells from bone marrow biopsies for single-cell RNA sequencing. STAR Protoc. 2021

Leimkühler NB*, Gleitz HFE*, Ronghui L*,...and Schneider RK. Heterogeneous bone-marrow stromal progenitors drive myelofibrosis via a druggable alarmin axis. Cell Stem Cell. 2021

Gleitz HFE, Dugourd AJF, Leimkühler NB, ... and Schneider RK. Increased CXCL4 expression in hematopoietic cells links inflammation and progression of bone marrow fibrosis in MPN. Blood. 2020

Full list of publications

Team